Transepithelial transport of a natural cholinesterase inhibitor, huperzine A, along the gastrointestinal tract: the role of ionization on absorption mechanism.
During recent years there has been increasing interest in the Lycopodium alkaloid huperzine A as a potential therapeutic agent for neurodegenerative diseases. This study aimed to characterize huperzine A's permeability across the enterocyte barrier along the gastrointestinal tract with an emphasis on the effect of ionization on the drug absorption. Intestinal permeability of huperzine A was evaluated by in vitro Caco-2 and parallel artificial membrane permeation assay models and by the ex vivo Ussing chamber model. The permeability rate was strongly dependent on the degree of ionization and increased with elevation of the donor medium pH in all studied models. The transport of the unionized fraction was similar to the permeability of the markers for passive transcellular diffusion. Addition of the paracellular permeability modulator palmitoylcarnitine in the Caco-2 model led to significant enhancement in the permeability of the ionized huperzine A fraction. No evidence of active transport of huperzine A was detected in this study. The Ussing chamber model experiments showed similar drug permeability along the entire rat intestine. In conclusion, huperzine A permeates the intestinal border mainly by passive transcellular diffusion whereas some fraction, dependent on the degree of huperzine A ionization, is absorbed by the paracellular route. Huperzine A's permeability characteristics pave the way to the development of its oral extended release dosage form. The specific population of the potential users of huperzine A and the high potency of this molecule support the rationale for such a delivery.
Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Gregory
G
Burshtein
Michael
M
Friedman
Sarit
S
Greenberg
Amnon
A
Hoffman
D000470:Alkaloids / Q000493:pharmacokinetics*; D000818:Animals; D000983:Antipyrine / Q000493:pharmacokinetics; D001692:Biological Transport / Q000187:drug effects; D001693:Biological Transport, Active / Q000187:drug effects*; D018938:Caco-2 Cells / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000493:pharmacokinetics*; D020895:Enterocytes / Q000187:drug effects; D041981:Gastrointestinal Tract / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D007477:Ions / Q000493:pharmacokinetics; D008297:Male; D008567:Membranes, Artificial; D008790:Metoprolol / Q000493:pharmacokinetics; D010172:Palmitoylcarnitine / Q000494:pharmacology; D010539:Permeability / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012717:Sesquiterpenes / Q000493:pharmacokinetics*
D000470:Alkaloids; D002800:Cholinesterase Inhibitors; D007477:Ions; D008567:Membranes, Artificial; D012717:Sesquiterpenes; C050426:huperzine A; D010172:Palmitoylcarnitine; D008790:Metoprolol; D000983:Antipyrine